Skip to main content

Advertisement

Table 2 Outcome measures

From: Panax ginseng therapy for chronic obstructive pulmonary disease: a clinical trial protocol and pilot study

  P. ginseng Placebo  
(mean ± standard deviation) (mean ± standard deviation) P value^
Baseline End of treatment Baseline End of treatment
Exacerbations Not applicable 0 Not applicable 0 1
FEV1 (L) 1.38 ± 0.63 1.40 ± 0.60 0.83 ± 0.10 0.80 ± 0.06 0.06
FVC (L) 2.79 ± 0.59 3.00 ± 0.50 2.33 ± 0.36 2.40 ± 0.46 0.11
FEV1/FVC 0.48 ± 0.13 0.40 ± 0.10 0.36 ± 0.06 0.30 ± 0.06 0.14
SGRQ 37.20 ± 12.85 32.20 ± 12.20 45.80 ± 10.54 34.40 ± 8.20 0.74
CAT (total score) 17.0 ± 6.32 16.20 ± 5.40 17.20 ± 4.87 14.40 ± 2.70 0.67
SF-36–General health 40.0 ± 23.18 48.00 ± 20.70 37.0 ± 14.40 39.0 ± 18.50 0.49
SF-36–Mental health 79.20 ± 17.75 82.40 ± 12.10 86.40 ± 7.26 89.60 ± 6.60 0.49
6MWT (m) 518.20 ± 10.01 502.80 ± 29.0 453.20 ± 60.27 453.0 ± 20.50 0.01*
  1. ^End of treatment between groups comparison.
  2. *P < 0.05 indicated significant difference between groups.
  3. 6MWT: 6-minute walking test, CAT: COPD Assessment Test, FEV1: forced expiratory volume in 1 second, FVC: forced vital capacity; SGRQ: St Georges Respiratory Questionnaire, SF-36: Short-form health survey (version 2).